Nagrestipen - CAS 166089-33-4

Nagrestipen, a variant of the human macrophage inflammatory protein-1 alpha (MIP-1α), also referred to as ECI 301, exhibits antitumor activity. It is employed in therapeutic trials focused on cancer, assessing its efficacy in the contexts of tumors, metastasis, radiation oncology, and the analysis of tumor metastasis [1].

166089-33-4

-20°C

Ice Packs

Peptide